Vertex Pharmaceuticals (VRTX) announced a reimbursement agreement with the Italian Medicines Agency for eligible transfusion-dependent beta thalassemia and severe sickle cell disease patients to access its CRISPR/Cas9 gene-edited therapy, CASGEVY. “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, senior VP of Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformative treatment provides to patients, families and the health care system.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals: Strong Buy Rating Backed by Promising Pipeline and Strategic Positioning
- Vertex Pharmaceuticals Positioned for Growth with FDA Support for Non-Opioid Analgesics
- FDA Draft Guidance Boosts Vertex Pharmaceuticals’ Prospects for Non-Opioid Analgesics
- Vertex Pharmaceuticals: Promising Growth and Strategic Positioning Justify Buy Rating
- Sionna Therapeutics initiated with a Strong Buy at Raymond James